Scilex Holding (SCLXW) Convertible Debt (2021 - 2022)
Scilex Holding (SCLXW) recorded quarterly Convertible Debt of $2.0 million in Q3 2022, little changed quarter-over-quarter from $2.0 million in Q2 2022.
Scilex Holding (SCLXW) Convertible Debt (2021 - 2022) Analysis & Trends
Scilex Holding's Convertible Debt history runs 2 years deep, the most recent figure standing at $2.0 million for Q3 2022.
- In Q3 2022, Convertible Debt changed N/A year-over-year to $2.0 million; the TTM figure through Sep 2022 stood at $2.0 million (changed N/A YoY), while the FY2021 annual figure was $483099.0, changed N/A from the prior year.
- Convertible Debt was $2.0 million for Q3 2022 at Scilex Holding, roughly flat from $2.0 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $2.0 million in Q3 2022 to a low of $483099.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.04 Mn |
| Jun 30, 2022 | 2.03 Mn |
| Mar 31, 2022 | 2.03 Mn |
| Dec 31, 2021 | 483,099.00 |